Coherus BioSciences (CHRS)
(Real Time Quote from BATS)
$1.02 USD
-0.02 (-1.92%)
Updated Sep 24, 2024 11:48 AM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Cash flow Statements
Fiscal Year End for Coherus BioSciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -237.89 | -291.75 | -287.10 | 132.24 | 89.83 |
Depreciation/Amortization & Depletion | 3.79 | 3.70 | 3.45 | 2.89 | 3.26 |
Net Change from Assets/Liabilities | -34.35 | -79.26 | 44.57 | -30.40 | -112.14 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 93.57 | 126.19 | 201.65 | 49.41 | 47.40 |
Net Cash From Operating Activities | -174.88 | -241.12 | -37.43 | 154.15 | 28.36 |
Property & Equipment | -0.29 | -2.04 | -1.29 | -7.23 | -1.82 |
Acquisition/ Disposition of Subsidiaries | 7.84 | 0.00 | 0.00 | 0.18 | 0.00 |
Investments | 138.14 | -127.38 | -1.12 | 0.15 | 0.16 |
Other Investing Activities | -1.05 | -37.43 | -136.00 | -7.50 | -11.08 |
Net Cash from Investing Activities | 144.64 | -166.85 | -138.41 | -14.40 | -12.73 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 74.22 | 9.37 | 54.30 | 17.43 | 5.56 |
Issuance (Repayment) of Debt | 0.00 | 49.93 | -0.67 | 203.60 | 72.96 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -4.62 | -4.97 | -1.75 | 2.92 | 10.86 |
Net Cash from Financing Activities | 69.60 | 54.33 | 51.88 | 223.95 | 89.37 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | -0.28 |
Net Change In Cash & Equivalents | 39.36 | -353.65 | -123.96 | 363.69 | 104.72 |
Cash at Beginning of Period | 63.99 | 417.64 | 541.60 | 177.91 | 73.19 |
Cash at End of Period | 103.34 | 63.99 | 417.64 | 541.60 | 177.91 |
Diluted Net EPS | -2.53 | -3.76 | -3.81 | 1.62 | 1.23 |
Fiscal Year End for Coherus BioSciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 89.95 | 102.88 | -237.89 | -158.24 | -118.60 |
Depreciation/Amortization & Depletion | 2.69 | 1.51 | 3.79 | 2.73 | 1.83 |
Net Change from Assets/Liabilities | 62.89 | -11.38 | -34.35 | -41.18 | -14.30 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -142.57 | -139.77 | 93.57 | 34.74 | 23.42 |
Net Cash From Operating Activities | 12.97 | -46.77 | -174.88 | -161.95 | -107.65 |
Property & Equipment | 0.00 | 0.00 | -0.29 | -0.25 | -0.25 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 7.84 | 7.77 | 0.62 |
Investments | 14.89 | 14.89 | 138.14 | 101.92 | 58.53 |
Other Investing Activities | 215.53 | 187.88 | -1.05 | 0.00 | 0.00 |
Net Cash from Investing Activities | 230.42 | 202.76 | 144.64 | 109.44 | 58.89 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.43 | 1.80 | 74.22 | 73.33 | 61.84 |
Issuance (Repayment) of Debt | -223.27 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 33.80 | -0.91 | -4.62 | -4.10 | -3.71 |
Net Cash from Financing Activities | -187.04 | 0.89 | 69.60 | 69.23 | 58.13 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 56.35 | 156.88 | 39.36 | 16.72 | 9.37 |
Cash at Beginning of Period | 103.34 | 103.34 | 63.99 | 63.99 | 63.99 |
Cash at End of Period | 159.69 | 260.23 | 103.34 | 80.71 | 73.36 |
Diluted Net EPS | -0.11 | 0.83 | -0.67 | -0.41 | -0.49 |